

Eric J Velazquez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8256321/publications.pdf>

Version: 2024-02-01

300
papers

31,060
citations

10389

72
h-index

4774

169
g-index

306
all docs

306
docs citations

306
times ranked

23120
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term results of surgical ventricular reconstruction and comparison with the Surgical Treatment for Ischemic Heart Failure trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2024, 167, 713-722.e7.	0.8	3
2	Renal function and coronary bypass surgery in patients with ischemic heart failure. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 663-672.e3.	0.8	5
3	Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1890-1899.e4.	0.8	5
4	Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF). <i>American Heart Journal</i> , 2022, 244, 107-115.	2.7	12
5	Progression of cardiac structure and function in people with human immunodeficiency virus. <i>Echocardiography</i> , 2022, 39, 268-277.	0.9	2
6	Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. <i>Circulation</i> , 2022, 145, 819-828.	1.6	7
7	Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial. <i>Journal of Cardiac Failure</i> , 2022, 28, 1563-1567.	1.7	1
8	Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2203-2213.	2.8	86
9	PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes. , 2022, 1, 100020.		5
10	Acute echocardiographic and hemodynamic response to his bundle pacing in patients with first-degree atrioventricular block. <i>Annals of Noninvasive Electrocardiology</i> , 2022, , e12954.	1.1	1
11	Current Landscape and Future Directions of Coronary Revascularization in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 577.	6.1	6
12	Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy. <i>JACC: Heart Failure</i> , 2021, 9, 115-123.	4.1	52
13	Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e007034.	3.9	27
14	Transition From an Open to Closed Staffing Model in the Cardiac Intensive Care Unit Improves Clinical Outcomes. <i>Journal of the American Heart Association</i> , 2021, 10, e018182.	3.7	17
15	Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0243291.	2.5	31
16	A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST). <i>European Heart Journal</i> , 2021, 42, 2536-2548.	2.2	17
17	Pragmatic Design of Randomized Clinical Trials for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 325-335.	4.1	22
18	Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). <i>American Journal of Cardiology</i> , 2021, 146, 99-106.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure, 2021, 8, 2866-2875.	3.1	7
20	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. ESC Heart Failure, 2021, 8, 2608-2616.	3.1	8
21	Understanding the role of left and right ventricular strain assessment in patients hospitalized with COVID-19. American Heart Journal Plus, 2021, 6, 100018.	0.6	9
22	The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. Journal of Cardiac Failure, 2021, 27, 1359-1366.	1.7	2
23	REVeAL-HF. JACC: Heart Failure, 2021, 9, 409-419.	4.1	14
24	Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes. American Journal of Medicine, 2021, 134, 1380-1388.e3.	1.5	9
25	2021: The American Association for Thoracic Surgery Expert Consensus Document: Coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 829-850.e1.	0.8	34
26	Restoring ventricular restoration: A call to re-evaluate a surgical therapy considered ineffective. Journal of Cardiac Surgery, 2021, 36, 693-695.	0.7	0
27	Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. American Journal of Hypertension, 2021, 34, 531-539.	2.0	1
28	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. Journal of Cardiac Failure, 2020, 26, 371-380.	1.7	25
29	Association between systolic ejection time and outcomes in heart failure by ejection fraction. European Journal of Heart Failure, 2020, 22, 1174-1182.	7.1	22
30	Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal of Cardiac Failure, 2020, 26, 270-275.	1.7	10
31	Durability and Efficacy of Tricuspid Valve Repair in Patients Undergoing Left Ventricular Assist Device Implantation. JACC: Heart Failure, 2020, 8, 141-150.	4.1	24
32	Speckle Tracking Analysis of Left Ventricular Systolic Function Following Traumatic Brain Injury: A Pilot Prospective Observational Cohort Study. Journal of Neurosurgical Anesthesiology, 2020, 32, 156-161.	1.2	8
33	Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. JAMA Cardiology, 2020, 5, 202.	6.1	57
34	Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. Journal of the American College of Cardiology, 2020, 76, 1034-1048.	2.8	32
35	Angiotensin-Neprilysin Inhibition in Black Americans. JACC: Heart Failure, 2020, 8, 859-866.	4.1	11
36	Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1506.	7.4	27

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020, 8, 834-843.	4.1	19
38	Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2020, 5, 1236.	6.1	46
39	Limitations of Natriuretic Peptide Levels in Establishing SGLT-2 Inhibitors for Heart Failure Care. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2086-2088.	2.8	3
40	Left Ventricular Systolic Function and Inpatient Mortality in Patients Hospitalized with Coronavirus Disease 2019 (COVID-19). <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 1414-1415.	2.8	13
41	Inpatient Transthoracic Echocardiography during the COVID-19 Pandemic: Evaluating a New Triage Process. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 1418-1419.	2.8	4
42	Implications of ST Changes During Normal Echocardiography—Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 1257.	5.1	0
43	Sex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 770-779.	4.1	36
44	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	3.9	8
45	Incremental prognostic value of echocardiography of left ventricular remodeling and diastolic function in STICH trial. <i>Cardiovascular Ultrasound</i> , 2020, 18, 17.	1.6	5
46	Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006963.	3.9	13
47	Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. <i>American Heart Journal</i> , 2020, 223, 87-97.	2.7	17
48	Prevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 142-148.	3.1	4
49	Implications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography. <i>JAMA Internal Medicine</i> , 2020, 180, 494.	5.1	18
50	Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting to Treat Ischemic Cardiomyopathy?. <i>JAMA Cardiology</i> , 2020, 5, 641.	6.1	4
51	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006645.	3.9	18
52	Early impairment of myocardial deformation assessed by regional speckle-tracking echocardiography in the indeterminate form of Chagas disease without fibrosis detected by cardiac magnetic resonance. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008795.	3.0	11
53	COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. <i>PLoS ONE</i> , 2020, 15, e0238829.	2.5	21
54	Title is missing!. , 2020, 15, e0238829.		0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0238829.		0
56	Title is missing!. , 2020, 15, e0238829.		0
57	Title is missing!. , 2020, 15, e0238829.		0
58	Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2019, 381, 739-748.	27.0	186
59	Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. <i>American Journal of Cardiology</i> , 2019, 124, 966-971.	1.6	11
60	Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2019, 124, 1298-1304.	1.6	13
61	Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. <i>ESC Heart Failure</i> , 2019, 6, 1233-1242.	3.1	13
62	Differential Impact of Mitral Valve Repair on Outcome of Coronary Artery Bypass Grafting with or without Surgical Ventricular Reconstruction in the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. <i>Structural Heart</i> , 2019, 3, 302-308.	0.6	3
63	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2019, 7, 878-887.	4.1	37
64	Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 373-381.	7.1	12
65	In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. <i>European Journal of Heart Failure</i> , 2019, 21, 1008-1011.	7.1	1
66	Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. <i>Circulation: Heart Failure</i> , 2019, 12, e005552.	3.9	43
67	Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. <i>European Heart Journal</i> , 2019, 40, 3345-3352.	2.2	59
68	Tricuspid Valve Regurgitation Immediately After Heart Transplant and Long-Term Outcomes. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1348-1355.	1.3	18
69	Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. <i>Circulation</i> , 2019, 139, 2285-2288.	1.6	129
70	Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. <i>International Journal of Cardiology</i> , 2019, 291, 36-41.	1.7	3
71	PCI and CABG for Treating Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 964-976.	2.8	282
72	Effects of a Cookstove Intervention on Cardiac Structure, Cardiac Function, and Blood Pressure in Western Kenya. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 427-430.	2.8	3

#	ARTICLE	IF	CITATIONS
73	Left Ventricular Global Longitudinal Strain Can Reliably Be Measured from a Single Apical Four-Chamber View in Patients with Heart Failure. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 317-318.	2.8	12
74	Predictors and Changes in Cardiac Hemodynamics and Geometry With Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2019, 123, 813-819.	1.6	11
75	Angiotensinâ€“Neprilysin Inhibition in Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2019, 380, 539-548.	27.0	848
76	Trends in cardiorespiratory fitness: The evolution of exercise treadmill testing at a single Academic Medical Center from 1970 to 2012. <i>American Heart Journal</i> , 2019, 210, 88-97.	2.7	6
77	High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved orâ€“Reducedâ€“Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 177-186.	2.8	37
78	Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 1-64.	2.8	1,208
79	Community Health Workers Improve Linkage to Hypertension Care in Westernâ€“Kenya. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1897-1906.	2.8	45
80	Death: The Simple Clinical Trial Endpoint. <i>Studies in Health Technology and Informatics</i> , 2019, 257, 86-91.	0.3	2
81	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. <i>Journal of Cardiac Failure</i> , 2018, 24, 255-265.	1.7	32
82	Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. <i>American Heart Journal</i> , 2018, 199, 176-177.	2.7	0
83	The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. <i>American Heart Journal</i> , 2018, 201, 17-24.	2.7	6
84	CABG or PCI for Diabetic Patients Withâ€“Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 828-831.	2.8	1
85	Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization. <i>Circulation</i> , 2018, 137, 771-780.	1.6	34
86	Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Leftâ€“Bundle Branch Block. <i>Journal of the American College of Cardiology</i> , 2018, 71, 306-317.	2.8	71
87	Prior Medications and the Cardiovascular Benefits From Combination Angiotensinâ€“Converting Enzyme Inhibition Plus Calcium Channel Blockade Among Highâ€“Risk Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	8
88	Impact of Intubation Time on Survival following Coronary Artery Bypass Grafting: Insights from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1256-1263.	1.3	1
89	Sudden cardiac death after acute heart failure hospital admission: insights from ASCENDâ€“HF. <i>European Journal of Heart Failure</i> , 2018, 20, 525-532.	7.1	29
90	Rationale and design of the comParlson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. <i>American Heart Journal</i> , 2018, 198, 145-151.	2.7	60

#	ARTICLE	IF	CITATIONS
91	Right Ventricular Longitudinal Strain Reproducibility Using Vendor-Dependent and Vendor-Independent Software. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 721-732.e5.	2.8	37
92	On Books, Covers, and Judgments in Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1747-1749.	5.3	0
93	Clinical Utility and Prognostic Value of Right Atrial Function in Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e006984.	2.6	59
94	Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization. <i>Circulation: Heart Failure</i> , 2018, 11, e005531.	3.9	26
95	Disrupting Fellow Education Through Group Texting. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3366-3369.	2.8	24
96	Childhood and adult exposure to secondhand tobacco smoke and cardiac structure and function: results from Echo-SOL. <i>Open Heart</i> , 2018, 5, e000831.	2.3	9
97	Variability in Ejection Fraction Measured By Echocardiography, Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. <i>JAMA Network Open</i> , 2018, 1, e181456.	5.9	143
98	Transcatheter Aortic Valve Replacement versus Medical Management among Patients with Aortic Stenosis and Left Ventricular Systolic Dysfunction. <i>Structural Heart</i> , 2018, 2, 388-395.	0.6	1
99	A meta-analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients. <i>ESC Heart Failure</i> , 2018, 5, 1150-1158.	3.1	32
100	Revascularization for Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 527-529.	4.1	4
101	Long-term outcomes of mitral regurgitation by type and severity. <i>American Heart Journal</i> , 2018, 203, 39-48.	2.7	19
102	Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. <i>Journal of Cardiac Failure</i> , 2018, 24, 496-503.	1.7	22
103	Crowdsourcing consensus: proposal of a novel method for assessing accuracy in echocardiography interpretation. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 1725-1730.	1.5	1
104	Clinical and Echocardiographic Predictors of Outcomes in Patients With Pulmonary Hypertension. <i>American Journal of Cardiology</i> , 2018, 122, 872-878.	1.6	20
105	Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. <i>Open Heart</i> , 2018, 5, e000752.	2.3	1
106	Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting. <i>Circulation</i> , 2017, 135, 1136-1144.	1.6	21
107	Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 119, 1017-1022.	1.6	36
108	Rethinking Revascularization in Left Ventricular Systolic Dysfunction. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	1

#	ARTICLE	IF	CITATIONS
109	Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 591-599.	1.8	19
110	Value of Cardiovascular Magnetic Resonance Imagingâ€“Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy. <i>JAMA Cardiology</i> , 2017, 2, 577.	6.1	5
111	Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the <sc>RELAX</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 893-900.	7.1	123
112	Improving on the diagnostic characteristics of echocardiography for pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1341-1349.	1.5	11
113	Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	9
114	Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	1.6	10
115	Associations between positive emotional well-being and stress-induced myocardial ischemia. <i>Journal of Psychosomatic Research</i> , 2017, 93, 14-18.	2.6	11
116	Comparison of Incidence of Left Ventricular Systolic Dysfunction Among Patients With Left Bundle Branch Block Versus Those With Normal QRS Duration. <i>American Journal of Cardiology</i> , 2017, 120, 1990-1997.	1.6	24
117	Prevalence and Outcomes of Leftâ€“Sided Valvular Heart Disease Associated With Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	66
118	Safety of coronary CT angiography and functional testing for stable chest pain in the PROMISE trial: A randomized comparison of test complications, incidental findings, and radiation dose. <i>Journal of Cardiovascular Computed Tomography</i> , 2017, 11, 373-382.	1.3	24
119	Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis. <i>Journal of Cardiac Failure</i> , 2017, 23, 659-665.	1.7	3
120	Usefulness of Myocardial Annular Velocity Change During Mental Stress to Predict Cardiovascular Outcome in Patients With Coronary Artery Disease (From the Responses of Mental Stress-Induced) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 1495-1500.	1.6	6
121	Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. <i>ESC Heart Failure</i> , 2017, 4, 432-439.	3.1	56
122	Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. <i>Current Cardiology Reports</i> , 2017, 19, 71.	2.9	147
123	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. <i>Circulation</i> , 2017, 135, 38-47.	1.6	16
124	Approaches to Sustainable Capacity Building for Cardiovascular Disease Care in Kenya. <i>Cardiology Clinics</i> , 2017, 35, 145-152.	2.2	4
125	Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya. <i>PLoS ONE</i> , 2017, 12, e0185204.	2.5	13
126	Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link?. <i>Respiratory Medicine</i> , 2016, 121, 4-12.	2.9	6

#	ARTICLE	IF	CITATIONS
127	Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	4
128	Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2016, 374, 1511-1520.	27.0	731
129	Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	178
130	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An <sc>ACCOMPLISH</sc> Substudy. <i>Journal of Clinical Hypertension</i> , 2016, 18, 299-307.	2.0	26
131	Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. <i>Circulation</i> , 2016, 134, 1314-1324.	1.6	127
132	Functional Mitral Regurgitation: Appraising the Evidence Behind Recommended Treatment Strategies. <i>Current Cardiology Reports</i> , 2016, 18, 128.	2.9	0
133	Clinical and echocardiographic predictors of mortality in acute pulmonary embolism. <i>Cardiovascular Ultrasound</i> , 2016, 14, 44.	1.6	47
134	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016, 1, 93-100.	5.5	1
135	Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction. <i>European Heart Journal</i> , 2016, 37, 2276-2286.	2.2	74
136	Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. <i>American Journal of Cardiology</i> , 2016, 117, 946-951.	1.6	23
137	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	1.6	47
138	An Approach to Improve the Negative Predictive Value and Clinical Utility of Transthoracic Echocardiography in Suspected Native Valve Infective Endocarditis. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 315-322.	2.8	24
139	Implementing a Continuous Quality Improvement Program in a High-Volume Clinical Echocardiography Laboratory. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	2.6	12
140	Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 365-373.	2.1	21
141	Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure: A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. <i>Global Heart</i> , 2016, 11, 97.	2.3	12
142	Tackling NCD in LMIC: Achievements and Lessons Learned From the NHLBIâ€™UnitedHealth Global Health Centers of Excellence Program. <i>Global Heart</i> , 2016, 11, 5.	2.3	36
143	Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (<sc>STICH</sc>) trial. <i>European Journal of Heart Failure</i> , 2015, 17, 725-734.	7.1	19
144	Torsemide Versus Furosemide in Heart Failure Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 438-443.	1.9	28

#	ARTICLE	IF	CITATIONS
145	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. <i>Future Cardiology</i> , 2015, 11, 585-595.	1.2	23
146	Building Sustainable Capacity for Cardiovascular Care at a Public Hospital in Western Kenya. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2550-2560.	2.8	35
147	Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL). <i>American Heart Journal</i> , 2015, 170, 455-464.e5.	2.7	5
148	Influence of QRS infarct score and QRS duration prior to transcatheter aortic valve replacement on follow-up left ventricular end systolic volume in patients with new persistent left bundle branch block. <i>Journal of Electrocardiology</i> , 2015, 48, 637-642.	0.9	5
149	Revascularization in Severe Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2015, 65, 615-624.	2.8	39
150	Clinical outcome as a function of the PR-interval--there is virtue in moderation: data from the Duke Databank for cardiovascular disease. <i>Europace</i> , 2015, 17, 978-985.	1.7	22
151	A reappraisal of loop diuretic choice in heart failure patients. <i>American Heart Journal</i> , 2015, 169, 323-333.	2.7	83
152	Implication of right ventricular dysfunction on long-term outcome in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting with or without surgical ventricular reconstruction. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 1312-1321.	0.8	37
153	Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2015, 372, 1291-1300.	27.0	1,179
154	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (<sc>VALIANT</sc>). <i>European Journal of Heart Failure</i> , 2015, 17, 301-312.	7.1	50
155	Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. <i>European Heart Journal</i> , 2015, 36, 2733-2741.	2.2	52
156	Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. <i>Future Cardiology</i> , 2015, 11, 471-484.	1.2	17
157	Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. <i>JACC: Heart Failure</i> , 2015, 3, 579-590.	4.1	60
158	Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. <i>Journal of Cardiac Failure</i> , 2015, 21, 741-750.	1.7	28
159	Relationship Between Daily Exposure to Biomass Fuel Smoke and Blood Pressure in High-Altitude Peru. <i>Hypertension</i> , 2015, 65, 1134-1140.	2.7	60
160	Use of outcome measures in pulmonary hypertension clinical trials. <i>American Heart Journal</i> , 2015, 170, 419-429.e3.	2.7	17
161	Comparison of Transesophageal and Transthoracic Echocardiographic Measurements of Mechanism and Severity of Mitral Regurgitation in Ischemic Cardiomyopathy (from the Surgical Treatment of) <i>Tj ETQq1 1 0.784314 rgBT10</i> Overlaid		
162	Impact of surgical ventricular reconstruction on sphericity index in patients with ischaemic cardiomyopathy: follow-up from the <sc>STICH</sc> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 453-463.	7.1	22

#	ARTICLE	IF	CITATIONS
163	Response to Letter Regarding Article, "Surgical Revascularization Is Associated With Maximal Survival in Patients With Ischemic Mitral Regurgitation: A 20-year Experience" Circulation, 2015, 131, e378-9.	1.6	1
164	Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. American Heart Journal, 2015, 169, 496-507.e1.	2.7	15
165	Genetic Variants Are Not Associated with Outcome in Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) Trials. Cardiology, 2015, 130, 69-81.	1.4	4
166	Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology, 2015, 66, 2092-2100.	2.8	48
167	Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2015, 373, 2314-2324.	27.0	453
168	The MitraClip and survival in patients with mitral regurgitation at high risk for surgery: A propensity-matched comparison. American Heart Journal, 2015, 170, 1050-1059.e3.	2.7	72
169	Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction. Circulation, 2015, 132, 720-730.	1.6	72
170	Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. JACC: Cardiovascular Imaging, 2015, 8, 1121-1129.	5.3	51
171	Predictors and Progression of Aortic Stenosis in Patients With Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2015, 115, 86-92.	1.6	20
172	Metabolomics analysis reveals insights into biochemical mechanisms of mental stress-induced left ventricular dysfunction. Metabolomics, 2015, 11, 571-582.	3.0	15
173	Implementation of Management Strategies for Diabetes and Hypertension: From Local to Global Health in Cardiovascular Diseases. Global Heart, 2015, 10, 31.	2.3	12
174	Quality-of-Life Outcomes With Coronary Artery Bypass Graft Surgery in Ischemic Left Ventricular Dysfunction. Annals of Internal Medicine, 2014, 161, 392.	3.9	58
175	Sex Differences in Platelet Reactivity and Cardiovascular and Psychological Response to Mental Stress in Patients With Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2014, 64, 1669-1678.	2.8	78
176	Myocardial viability and impact of surgical ventricular reconstruction on outcomes of patients with severe left ventricular dysfunction undergoing coronary artery bypass surgery: Results of the Surgical Treatment for Ischemic Heart Failure trial. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2677-2684.e1.	0.8	24
177	PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. American Heart Journal, 2014, 167, 796-803.e1.	2.7	104
178	Comprehensive Assessment of Right Ventricular Function in Patients with Pulmonary Hypertension with Global Longitudinal Peak Systolic Strain Derived from Multiple Right Ventricular Views. Journal of the American Society of Echocardiography, 2014, 27, 657-665.e3.	2.8	76
179	Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. Breast Cancer Research and Treatment, 2014, 143, 531-539.	2.5	45
180	Impaired Resting Myocardial Annular Velocities Are Independently Associated With Mental Stress-Induced Ischemia in Coronary Heart Disease. JACC: Cardiovascular Imaging, 2014, 7, 351-361.	5.3	15

#	ARTICLE	IF	CITATIONS
181	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. <i>JACC: Heart Failure</i> , 2014, 2, 159-165.	4.1	91
182	Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. <i>JACC: Heart Failure</i> , 2014, 2, 335-343.	4.1	43
183	Extent of Coronary and Myocardial Disease and Benefit From Surgical Revascularization in LV Dysfunction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 553-561.	2.8	92
184	Surgical Revascularization Is Associated With Maximal Survival in Patients With Ischemic Mitral Regurgitation. <i>Circulation</i> , 2014, 129, 2547-2556.	1.6	84
185	Factors Associated With Isolated Right Heart Failure in Women: A Pilot Study From Western Kenya. <i>Global Heart</i> , 2014, 9, 249.	2.3	15
186	Abstract 16683: Reduced Lung Function is Associated With Decreased Ejection Fraction and Decreased Left Ventricular Size in Patients in a Tertiary Care Center. <i>Circulation</i> , 2014, 130, .	1.6	0
187	Abstract 18699: Negative Predictive Value of Transthoracic Echocardiography for Infective Endocarditis in the Modern Era. <i>Circulation</i> , 2014, 130, .	1.6	2
188	Abstract 17973: Biomass Fuel Use is Associated With Elevated Blood Pressure and Hypertension Status in Puno, Peru. <i>Circulation</i> , 2014, 130, .	1.6	0
189	Early Echocardiographic Deformation Analysis for the Prediction of Sudden Cardiac Death and Life-Threatening Arrhythmias After Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 851-860.	5.3	90
190	Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. <i>American Journal of Medicine</i> , 2013, 126, 501-508.	1.5	56
191	Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2013, 6, 862-868.	3.9	21
192	Mechanisms of Functional Mitral Regurgitation in Ischemic Cardiomyopathy Determined by Transesophageal Echocardiography (from the Surgical Treatment for Ischemic Heart Failure Trial). <i>American Journal of Cardiology</i> , 2013, 112, 1812-1818.	1.6	32
193	The STICH Trial (Surgical Treatment for Ischemic Heart Failure). <i>JACC: Heart Failure</i> , 2013, 1, 400-408.	4.1	82
194	Inducible Myocardial Ischemia and Outcomes in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1860-1870.	2.8	163
195	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. <i>Lancet</i> , 2013, 381, 537-545.	13.7	132
196	Prevalence and Clinical Characteristics of Mental Stress-Induced Myocardial Ischemia in Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 714-722.	2.8	80
197	Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. <i>Journal of Electrocardiology</i> , 2013, 46, 45-50.	0.9	23
198	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1268.	7.4	976

#	ARTICLE	IF	CITATIONS
199	Prediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2365-2373.	2.8	320
200	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533.	7.4	410
201	Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. <i>Circulation: Heart Failure</i> , 2013, 6, 461-472.	3.9	28
202	Depressive Symptoms and Mental Stress-Induced Myocardial Ischemia in Patients With Coronary Heart Disease. <i>Psychosomatic Medicine</i> , 2013, 75, 822-831.	2.0	41
203	Influence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease. <i>Circulation: Heart Failure</i> , 2013, 6, 443-450.	3.9	27
204	Effect of Escitalopram on Mental Stress-Induced Myocardial Ischemia. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2139.	7.4	85
205	Heart Failure in Sub-Saharan Africa. <i>Current Cardiology Reviews</i> , 2013, 9, 157-173.	1.5	79
206	Myocardial Imaging Should Not Exclude Patients With Ischemic Heart Failure From Coronary Revascularization. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 271-279.	2.6	10
207	Renal outcomes in hypertensive Black patients at high cardiovascular risk. <i>Kidney International</i> , 2012, 81, 568-576.	5.2	31
208	Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2296-2304.	27.0	790
209	Mechanisms and Predictors of Mitral Regurgitation after High-Risk Myocardial Infarction. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 535-542.	2.8	31
210	Variability of Global Left Ventricular Deformation Analysis Using Vendor Dependent and Independent Two-Dimensional Speckle-Tracking Software in Adults. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 1195-1203.	2.8	186
211	Core Lab Analysis of Baseline Echocardiographic Studies in the STICH Trial and Recommendation for Use of Echocardiography in Future Clinical Trials. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 327-336.	2.8	63
212	Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: Results from the Duke Databank for Cardiovascular Disease (DDCD). <i>American Heart Journal</i> , 2012, 164, 434-441.	2.7	49
213	Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial. <i>Circulation</i> , 2012, 125, 2639-2648.	1.6	210
214	Long-Term Survival of Patients With Ischemic Cardiomyopathy Treated by Coronary Artery Bypass Grafting Versus Medical Therapy. <i>Annals of Thoracic Surgery</i> , 2012, 93, 523-530.	1.3	61
215	Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. <i>European Journal of Heart Failure</i> , 2011, 13, 148-153.	7.1	80
216	LV Thrombus Detection by Routine Echocardiography. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 702-712.	5.3	166

#	ARTICLE	IF	CITATIONS
217	Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. <i>New England Journal of Medicine</i> , 2011, 364, 1617-1625.	27.0	734
218	Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. <i>New England Journal of Medicine</i> , 2011, 364, 1607-1616.	27.0	1,035
219	Chronic noncommunicable cardiovascular and pulmonary disease in sub-Saharan Africa: An academic model for countering the epidemic. <i>American Heart Journal</i> , 2011, 161, 842-847.	2.7	31
220	Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. <i>American Heart Journal</i> , 2011, 161, 1156-1162.	2.7	17
221	Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. <i>American Heart Journal</i> , 2011, 162, 685-691.	2.7	39
222	Utility of a Simple Algorithm to Grade Diastolic Dysfunction and Predict Outcome After Coronary Artery Bypass Graft Surgery. <i>Annals of Thoracic Surgery</i> , 2011, 91, 1844-1850.	1.3	86
223	Diuretic Strategies in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 364, 797-805.	27.0	1,363
224	Prevalence and predictors of mechanical dyssynchrony as defined by phase analysis in patients with left ventricular dysfunction undergoing gated SPECT myocardial perfusion imaging. <i>Journal of Nuclear Cardiology</i> , 2011, 18, 24-30.	2.1	40
225	Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorothiazide on 24-Hour Ambulatory Systolic Blood Pressure Control. <i>Hypertension</i> , 2011, 57, 174-179.	2.7	55
226	Hypertension and Obesity as Cardiovascular Risk Factors among HIV Seropositive Patients in Western Kenya. <i>PLoS ONE</i> , 2011, 6, e22288.	2.5	99
227	Does Myocardial Perfusion Imaging Provide Incremental Prognostic Information to Left Ventricular Ejection Fraction?. <i>Current Cardiology Reports</i> , 2010, 12, 155-161.	2.9	10
228	Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 122, 597-602.	1.6	195
229	The interrelationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. <i>European Journal of Heart Failure</i> , 2010, 12, 1229-1237.	7.1	45
230	The STICH trial: evidence-based conclusions. <i>European Journal of Heart Failure</i> , 2010, 12, 1028-1030.	7.1	19
231	Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 121, 1096-1103.	1.6	96
232	Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. <i>European Heart Journal</i> , 2010, 31, 211-221.	2.2	44
233	STICH (Surgical Treatment for Ischemic Heart Failure) Trial Enrollment. <i>Journal of the American College of Cardiology</i> , 2010, 56, 490-498.	2.8	41
234	Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 77-85.	2.8	215

#	ARTICLE	IF	CITATIONS
235	Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1812-1822.	2.8	263
236	Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). <i>American Heart Journal</i> , 2010, 160, 145-151.	2.7	33
237	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. <i>Lancet, The</i> , 2010, 375, 1173-1181.	13.7	472
238	Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. <i>European Heart Journal</i> , 2009, 30, 2226-2232.	2.2	95
239	Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). <i>European Heart Journal</i> , 2009, 30, 1450-1456.	2.2	47
240	Coronary Bypass Surgery with or without Surgical Ventricular Reconstruction. <i>New England Journal of Medicine</i> , 2009, 360, 1705-1717.	27.0	652
241	Impact of Left Ventricular Dysfunction on Hospital Mortality Among Patients Undergoing Elective Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2009, 103, 355-360.	1.6	47
242	Usefulness of the Duke Sudden Cardiac Death Risk Score for Predicting Sudden Cardiac Death in Patients With Angiographic (>75% Narrowing) Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2009, 104, 1624-1630.	1.6	25
243	Use of phase analysis of gated SPECT perfusion imaging to quantify dyssynchrony in patients with mild-to-moderate left ventricular dysfunction. <i>Journal of Nuclear Cardiology</i> , 2009, 16, 888-894.	2.1	31
244	Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2009, 11, 292-298.	7.1	102
245	Evaluation of mechanical dyssynchrony and myocardial perfusion using phase analysis of gated SPECT imaging in patients with left ventricular dysfunction. <i>Journal of Nuclear Cardiology</i> , 2008, 15, 663-670.	2.1	64
246	Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 101, 925-929.	1.6	22
247	Emerging Role of Myocardial Perfusion Imaging to Evaluate Patients for Cardiac Resynchronization Therapy—Conflicts of interest: Dr. Garcia has an ownership interest in and serves as a consultant and advisory board member for Syntermed, Inc., Atlanta, Georgia. Dr. Garcia also receives royalties from the sale of clinical software that was used as part of this research. Dr. Borges-Neto and Dr. Trimble have received research support from the Duke-Medtronic Strategic Alliance, which funded some of	1.6	21
248	Relation of Mortality to Failure to Prescribe Beta Blockers Acutely in Patients With Sustained Ventricular Tachycardia and Ventricular Fibrillation Following Acute Myocardial Infarction (from) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22</i> <i>Cardiology</i> , 2008, 102, 1427-1432.	1.6	50
249	Detection of Left Ventricular Thrombus by Delayed-Enhancement Cardiovascular Magnetic Resonance. <i>Journal of the American College of Cardiology</i> , 2008, 52, 148-157.	2.8	271
250	Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2008, 1, 582-591.	5.3	227
251	Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. <i>American Heart Journal</i> , 2008, 155, 87-93.	2.7	33
252	High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. <i>American Heart Journal</i> , 2008, 155, 706-711.	2.7	29

#	ARTICLE	IF	CITATIONS
253	Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. <i>New England Journal of Medicine</i> , 2008, 359, 2417-2428.	27.0	1,849
254	Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF). <i>Journal of Cardiac Failure</i> , 2008, 14, 777-784.	1.7	43
255	Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study). <i>American Journal of Cardiology</i> , 2008, 101, 607-612.	1.6	197
256	Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. <i>Blood Pressure</i> , 2008, 17, 7-17.	1.5	49
257	Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. <i>European Heart Journal</i> , 2008, 30, 56-65.	2.2	117
258	Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. <i>European Heart Journal</i> , 2008, 29, 748-756.	2.2	102
259	Response to The J-Point Revisited. <i>Hypertension</i> , 2008, 51, .	2.7	0
260	Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. <i>Hypertension</i> , 2008, 51, 48-54.	2.7	69
261	Repeatability and reproducibility of phase analysis of gated single-photon emission computed tomography myocardial perfusion imaging used to quantify cardiac dyssynchrony. <i>Nuclear Medicine Communications</i> , 2008, 29, 374-381.	1.1	137
262	Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. <i>European Heart Journal</i> , 2007, 28, 326-333.	2.2	88
263	Exceptional early blood pressure control rates: The ACCOMPLISH trial. <i>Blood Pressure</i> , 2007, 16, 80-86.	1.5	114
264	Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. <i>Blood Pressure</i> , 2007, 16, 13-19.	1.5	65
265	Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. <i>Heart Rhythm</i> , 2007, 4, 308-313.	0.7	21
266	The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1238-1245.	2.8	72
267	Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings. <i>Journal of Nuclear Cardiology</i> , 2007, 14, 165-173.	2.1	17
268	Racial Disparity in the Utilization of Implantable-Cardioverter Defibrillators Among Patients With Prior Myocardial Infarction and an Ejection Fraction of $\geq 35\%$. <i>American Journal of Cardiology</i> , 2007, 100, 924-929.	1.6	72
269	The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 134, 1540-1547.e4.	0.8	182
270	Comparison of Regional Versus Global Assessment of Left Ventricular Function in Patients with Left Ventricular Dysfunction, Heart Failure, or Both After Myocardial Infarction: The Valsartan in Acute Myocardial Infarction Echocardiographic Study. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 1462-1465.	2.8	46

#	ARTICLE	IF	CITATIONS
271	Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. <i>Heart Rhythm</i> , 2006, 3, 313-316.	0.7	49
272	The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 726-733.	2.8	149
273	The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry. <i>American Heart Journal</i> , 2006, 151, 206-212.	2.7	66
274	Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>American Heart Journal</i> , 2006, 152, 183-189.	2.7	24
275	Contemporary performance of surgical ventricular restoration procedures: Data from the Society of Thoracic Surgeons' National Cardiac Database. <i>American Heart Journal</i> , 2006, 152, 494-499.	2.7	25
276	Epidemiology of Heart Failure and Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Prevalence, Clinical Characteristics, and Prognostic Importance. <i>American Journal of Cardiology</i> , 2006, 97, 13-25.	1.6	185
277	Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2006, 8, 591-598.	7.1	111
278	Navigating the Crossroads of Coronary Artery Disease and Heart Failure. <i>Circulation</i> , 2006, 114, 1202-1213.	1.6	320
279	Outcomes by Race and Etiology of Patients With Left Ventricular Systolic Dysfunction. <i>American Journal of Cardiology</i> , 2005, 96, 956-963.	1.6	25
280	To STICH or not to STICH: We know the answer, but do we understand the question?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 129, 246-249.	0.8	42
281	Therapies to prevent heart failure post-myocardial infarction. <i>Current Heart Failure Reports</i> , 2005, 2, 174-182.	3.3	19
282	Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction. <i>Circulation</i> , 2005, 111, 3411-3419.	1.6	251
283	Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>New England Journal of Medicine</i> , 2005, 352, 2581-2588.	27.0	721
284	Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. <i>European Heart Journal</i> , 2005, 26, 2114-2119.	2.2	28
285	Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>American Heart Journal</i> , 2005, 150, 323-329.	2.7	23
286	Acute Heart Failure Complicating Acute Coronary Syndromes. <i>Circulation</i> , 2004, 109, 440-442.	1.6	30
287	Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. <i>Circulation</i> , 2004, 110, 1572-1578.	1.6	201
288	Prognostic usefulness of left ventricular thrombus by echocardiography in dilated cardiomyopathy in predicting stroke, transient ischemic attack, and death. <i>American Journal of Cardiology</i> , 2004, 93, 500-503.	1.6	41

#	ARTICLE	IF	CITATIONS
289	Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization. American Journal of Cardiology, 2004, 93, 1275-1279.	1.6	20
290	An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. European Heart Journal, 2004, 25, 1911-1919.	2.2	126
291	Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. New England Journal of Medicine, 2004, 351, 1285-1295.	27.0	1,712
292	Importance of echocardiography in patients with severe nonischemic heart failure: the second prospective randomized amlodipine survival evaluation (PRAISE-2) echocardiographic study. American Heart Journal, 2004, 147, 151-157.	2.7	26
293	Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal, 2004, 148, 122-128.	2.7	44
294	Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. American Journal of Hypertension, 2004, 17, 793-801.	2.0	97
295	Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease?. American Heart Journal, 2003, 145, 758-767.	2.7	21
296	Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. American Heart Journal, 2003, 146, 621-627.	2.7	55
297	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine, 2003, 349, 1893-1906.	27.0	2,240
298	VALsartan In Acute myocardial infarction (VALIANT) trial: baseline characteristics in context. European Journal of Heart Failure, 2003, 5, 537-544.	7.1	76
299	Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease) Tj ETQq1 1 0.784314 rgsB/Overlo	1.0	14
300	Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal, 2000, 140, 727-750.	2.7	162